Hsbc Holdings PLC Has $419,000 Holdings in CryoPort, Inc. $CYRX

Hsbc Holdings PLC increased its stake in shares of CryoPort, Inc. (NASDAQ:CYRX) by 96.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 62,405 shares of the company’s stock after purchasing an additional 30,671 shares during the period. Hsbc Holdings PLC owned approximately 0.12% of CryoPort worth $419,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. Point72 Asia Singapore Pte. Ltd. grew its stake in shares of CryoPort by 148.7% during the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company’s stock worth $28,000 after purchasing an additional 2,120 shares during the period. Sierra Summit Advisors LLC grew its stake in CryoPort by 5.0% in the first quarter. Sierra Summit Advisors LLC now owns 45,060 shares of the company’s stock valued at $274,000 after acquiring an additional 2,150 shares during the period. Price T Rowe Associates Inc. MD grew its stake in CryoPort by 8.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 60,003 shares of the company’s stock valued at $467,000 after acquiring an additional 4,902 shares during the period. Charles Schwab Investment Management Inc. grew its stake in CryoPort by 1.4% in the first quarter. Charles Schwab Investment Management Inc. now owns 370,302 shares of the company’s stock valued at $2,251,000 after acquiring an additional 5,207 shares during the period. Finally, Graham Capital Management L.P. grew its stake in CryoPort by 24.9% in the fourth quarter. Graham Capital Management L.P. now owns 28,460 shares of the company’s stock valued at $221,000 after acquiring an additional 5,667 shares during the period. 92.90% of the stock is owned by institutional investors and hedge funds.

CryoPort Stock Performance

CYRX opened at $8.81 on Wednesday. CryoPort, Inc. has a 52-week low of $4.58 and a 52-week high of $9.48. The firm has a market capitalization of $441.12 million, a PE ratio of 6.62 and a beta of 1.62. The company has a debt-to-equity ratio of 0.39, a quick ratio of 15.47 and a current ratio of 16.24. The business’s 50-day simple moving average is $7.91 and its 200 day simple moving average is $6.74.

CryoPort (NASDAQ:CYRX) last released its earnings results on Tuesday, August 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.09). CryoPort had a negative return on equity of 9.79% and a net margin of 37.21%.The company had revenue of $45.45 million for the quarter, compared to the consensus estimate of $41.74 million. CryoPort has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that CryoPort, Inc. will post -0.99 earnings per share for the current fiscal year.

Insider Buying and Selling at CryoPort

In other news, CFO Robert Stefanovich sold 9,300 shares of the stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $8.67, for a total value of $80,631.00. Following the completion of the transaction, the chief financial officer directly owned 207,213 shares in the company, valued at approximately $1,796,536.71. This represents a 4.30% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Robert J. Hariri sold 5,000 shares of the firm’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $8.60, for a total value of $43,000.00. Following the transaction, the director directly owned 26,275 shares of the company’s stock, valued at approximately $225,965. This represents a 15.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 492,247 shares of company stock valued at $3,384,579 over the last ninety days. 10.10% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on CYRX shares. Needham & Company LLC reissued a “buy” rating and issued a $11.00 target price on shares of CryoPort in a research note on Thursday, May 8th. BTIG Research decreased their target price on CryoPort from $13.00 to $10.00 and set a “buy” rating for the company in a research note on Monday, July 7th. KeyCorp raised CryoPort from a “sector weight” rating to an “overweight” rating and set a $15.00 target price for the company in a research note on Wednesday, August 6th. Stephens started coverage on CryoPort in a research note on Tuesday, July 22nd. They issued an “overweight” rating and a $13.00 target price for the company. Finally, Leerink Partners raised CryoPort from a “market perform” rating to an “outperform” rating and set a $16.00 target price for the company in a research note on Wednesday, August 6th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, CryoPort currently has an average rating of “Buy” and an average price target of $12.00.

About CryoPort

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.